Cargando…

Immunological Dysregulation in Multiple Myeloma Microenvironment

Multiple Myeloma (MM) is a systemic hematologic disease due to uncontrolled proliferation of monoclonal plasma cells (PC) in bone marrow (BM). Emerging in other solid and liquid cancers, the host immune system and the microenvironment have a pivotal role for PC growth, proliferation, survival, migra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Romano, Alessandra, Conticello, Concetta, Cavalli, Maide, Vetro, Calogero, La Fauci, Alessia, Parrinello, Nunziatina Laura, Di Raimondo, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4071780/ https://www.ncbi.nlm.nih.gov/pubmed/25013764 http://dx.doi.org/10.1155/2014/198539

Ejemplares similares

Salvage Therapy of Multiple Myeloma: The New Generation Drugs
por: Romano, Alessandra, et al.
Publicado: (2014)

Immunological Deregulation in Classic Hodgkin Lymphoma
por: Romano, Alessandra, et al.
Publicado: (2014)

Lenalidomide and Pomalidomide Improve Function and Induce FcγRI/CD64 in Multiple Myeloma Neutrophils
por: Romano, Alessandra, et al.
Publicado: (2021)

PB2072: CIRCULATING CD71+ MYELOID PRECURSORS IN MGUS AND MULTIPLE MYELOMA: A PROSPECTIVE SURVEY
por: Parrinello, Nunziatina Laura, et al.
Publicado: (2023)

Serum free light chains and multiple myeloma: Is it time to extend their application?
por: Markovic, Uros, et al.
Publicado: (2020)

TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma
por: Giallongo, Cesarina, et al.
Publicado: (2019)

PB2093: OVERALL SURVIVAL IN RELAPSED-REFRACTORY MYELOMA PATIENTS DEPENDS ON CIRCULATING PLASMA CELLS QUANTITATION
por: Parrinello, Nunziatina Laura, et al.
Publicado: (2023)

Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives
por: Romano, Alessandra, et al.
Publicado: (2019)

How we manage smoldering multiple myeloma
por: Romano, Alessandra, et al.
Publicado: (2020)

Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC)
por: Giallongo, Cesarina, et al.
Publicado: (2016)

Bortezomib modulates CHIT1 and YKL40 in monocyte-derived osteoclast and in myeloma cells
por: Tibullo, Daniele, et al.
Publicado: (2015)

Correction: TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma
por: Giallongo, Cesarina, et al.
Publicado: (2019)

Multiple Myeloma in 2023 Ways: From Trials to Real Life
por: Fazio, Manlio, et al.
Publicado: (2023)

Lactate trafficking inhibition restores sensitivity to proteasome inhibitors and orchestrates immuno‐microenvironment in multiple myeloma
por: Barbato, Alessandro, et al.
Publicado: (2023)

CXCL12/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment
por: Giallongo, Cesarina, et al.
Publicado: (2022)

Oral Lesion as Unusual First Manifestation of Multiple Myeloma: Case Reports and Review of the Literature
por: Romano, A., et al.
Publicado: (2014)

Plasticity of High-Density Neutrophils in Multiple Myeloma is Associated with Increased Autophagy Via STAT3
por: Puglisi, Fabrizio, et al.
Publicado: (2019)

A rare case of multiple myeloma with intracranial extramedullary relapse: One or more myeloma clones?
por: Markovic, Uros, et al.
Publicado: (2019)

Immunological Subsets Characterization in Newly Diagnosed Relapsing–Remitting Multiple Sclerosis
por: D’Amico, Emanuele, et al.
Publicado: (2022)

P852: ARGININE DEPRIVATION INDUCES ACQUISITION OF A SENESCENT PHENOTYPE AND FAVORS GENOMIC INSTABILITY IN MULTIPLE MYELOMA PLASMA CELLS
por: Romano, Alessandra, et al.
Publicado: (2023)

Proteomic Analysis Reveals Autophagy as Pro-Survival Pathway Elicited by Long-Term Exposure with 5-Azacitidine in High-Risk Myelodysplasia
por: Romano, Alessandra, et al.
Publicado: (2017)

The NLR and LMR ratio in newly diagnosed MM patients treated upfront with novel agents
por: Romano, Alessandra, et al.
Publicado: (2017)

Inhibition of TLR4 Signaling Affects Mitochondrial Fitness and Overcomes Bortezomib Resistance in Myeloma Plasma Cells
por: Giallongo, Cesarina, et al.
Publicado: (2020)

Monocytic Myeloid Derived Suppressor Cells in Hematological Malignancies
por: Palumbo, Giuseppe Alberto, et al.
Publicado: (2019)

P43 CIRCULATING CLONAL PLASMA CELLS AT START OF SALVAGE REGIMEN PROVIDE POWERFUL PROGNOSTICATION BIOMARKER IN MULTIPLE MYELOMA PATIENTS AT FIRST RELAPSE
por: Romano, A., et al.
Publicado: (2023)

Role of Serum Free Light Chain Assay in Relapsed/Refractory Multiple Myeloma. A Real-Life Unicentric Retrospective Study
por: Markovic, Uros, et al.
Publicado: (2021)

Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens
por: Botta, Cirino, et al.
Publicado: (2021)

Potential clinical impact of T-cell lymphocyte kinetics monitoring in patients with B cell precursors acute lymphoblastic leukemia treated with blinatumomab: a single-center experience
por: Duminuco, Andrea, et al.
Publicado: (2023)

Combined Inhibition of Bcl2 and Bcr-Abl1 Exercises Anti-Leukemia Activity but Does Not Eradicate the Primitive Leukemic Cells
por: Massimino, Michele, et al.
Publicado: (2021)

Clinical Impact of the Immunome in Lymphoid Malignancies: The Role of Myeloid-Derived Suppressor Cells
por: Vetro, Calogero, et al.
Publicado: (2015)

Clinical outcome of SARS-CoV-2 infections occurring in multiple myeloma patients after vaccination and prophylaxis with tixagevimab/cilgavimab
por: Duminuco, Andrea, et al.
Publicado: (2023)

Antiproliferative and Antiangiogenic Effects of Punica granatum Juice (PGJ) in Multiple Myeloma (MM)
por: Tibullo, Daniele, et al.
Publicado: (2016)

A Real-Life Survey of Venous Thromboembolic Events Occurring in Myeloma Patients Treated in Third Line with Second-Generation Novel Agents
por: Calafiore, Valeria, et al.
Publicado: (2020)

Heme oxygenase-1 nuclear translocation regulates bortezomib-induced cytotoxicity and mediates genomic instability in myeloma cells
por: Tibullo, Daniele, et al.
Publicado: (2016)

Lenalidomide plus Dexamethasone Combination as First-Line Oral Therapy of Multiple Myeloma Patients: A Unicentric Real-Life Study
por: Del Fabro, Vittorio, et al.
Publicado: (2023)

Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
por: Parisi, Marina Silvia, et al.
Publicado: (2019)

The prognostic value of the myeloid-mediated immunosuppression marker Arginase-1 in classic Hodgkin lymphoma
por: Romano, Alessandra, et al.
Publicado: (2016)

A case of high‐risk AML in a patient with advanced systemic mastocytosis
por: Fazio, Manlio, et al.
Publicado: (2023)

Bone turnover markers in patients with type 1 Gaucher disease
por: Giuffrida, Gaetano, et al.
Publicado: (2012)

P01: ARGININE STARVATION IN MULTIPLE MYELOMA MICROENVIRONMENT CONVEYS BORTEZOMIB REFRACTORINESS VIA TLR4 PATHWAY.
por: Romano, A, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_guo6vc37ag79ug1bo2tahdrb87